Switch theme
Sign up to access all valuation multiples
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
2021
123
Last FY Revenue n/a
LTM EBITDA -$51.0M
$20.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vicarious Surgical has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$51.0M.
In the most recent fiscal year, Vicarious Surgical achieved revenue of n/a and an EBITDA of -$61.1M.
Vicarious Surgical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vicarious Surgical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$51.0M | XXX | -$61.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$65.4M | XXX | -$66.6M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$62.9M | XXX | -$63.2M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Vicarious Surgical's stock price is $8.
Vicarious Surgical has current market cap of $44.7M, and EV of $20.9M.
See Vicarious Surgical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20.9M | $44.7M | XXX | XXX | XXX | XXX | $-10.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Vicarious Surgical has market cap of $44.7M and EV of $20.9M.
Vicarious Surgical's trades at n/a EV/Revenue multiple, and -0.3x EV/EBITDA.
Equity research analysts estimate Vicarious Surgical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vicarious Surgical has a P/E ratio of -0.7x.
See valuation multiples for Vicarious Surgical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $44.7M | XXX | $44.7M | XXX | XXX | XXX |
| EV (current) | $20.9M | XXX | $20.9M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.4x | XXX | -0.3x | XXX | XXX | XXX |
| EV/EBIT | -0.3x | XXX | -0.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.7x | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVicarious Surgical's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.5M for the same period.
Vicarious Surgical's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vicarious Surgical's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vicarious Surgical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -1% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vicarious Surgical acquired XXX companies to date.
Last acquisition by Vicarious Surgical was XXXXXXXX, XXXXX XXXXX XXXXXX . Vicarious Surgical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vicarious Surgical founded? | Vicarious Surgical was founded in 2021. |
| Where is Vicarious Surgical headquartered? | Vicarious Surgical is headquartered in United States of America. |
| How many employees does Vicarious Surgical have? | As of today, Vicarious Surgical has 123 employees. |
| Who is the CEO of Vicarious Surgical? | Vicarious Surgical's CEO is Mr. Adam Sachs. |
| Is Vicarious Surgical publicy listed? | Yes, Vicarious Surgical is a public company listed on NYS. |
| What is the stock symbol of Vicarious Surgical? | Vicarious Surgical trades under RBOT ticker. |
| When did Vicarious Surgical go public? | Vicarious Surgical went public in 2021. |
| Who are competitors of Vicarious Surgical? | Similar companies to Vicarious Surgical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Vicarious Surgical? | Vicarious Surgical's current market cap is $44.7M |
| Is Vicarious Surgical profitable? | Yes, Vicarious Surgical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Vicarious Surgical? | Vicarious Surgical's last 12 months EBITDA is -$51.0M. |
| What is the current EV/EBITDA multiple of Vicarious Surgical? | Current EBITDA multiple of Vicarious Surgical is -0.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
